Browse studies

Find your next paid study

1 recruiting study matching your filters

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pha…

Advanced or Metastatic Solid TumorsBreast CancerOvarian Cancer+10 more

Estimated

~$10 – $8,750

858 Therapeutics, Inc.NCT06395519